l gsB
UNMC_Acronym_Vert_sm_4c
University of Nebraska Medical Center

Moderna Files FDA Application for the LP.8.1 Targeting COVID-19 Vaccine

Moderna

Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2025-2026 formula, targeting the SARS-CoV-2 variant LP.8.1. The submission is based on guidance from the U.S. FDA, which advised that COVID-19 vaccines should be updated to a monovalent JN.1 lineage, with a preference for the LP.8.1 variant.

Continue reading

twitter facebook bluesky email print

Leave a comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.